Shin Nippon Biomedical Laboratories（SBLO.F）株式概要株式会社新日本バイオメディカル研究所は医薬品開発業務受託機関として、国内外における医薬品開発業務およびメディポリス事業を展開している。 詳細SBLO.F ファンダメンタル分析スノーフレーク・スコア評価2/6将来の成長0/6過去の実績1/6財務の健全性4/6配当金4/6報酬株価収益率（ 10.4 x） US市場（ 19.1 x）を下回っています。リスク分析株式の流動性は非常に低い 多額の負債を抱えている すべてのリスクチェックを見るSBLO.F Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair ValueUS$Current PriceUS$7.005.7% 割安 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-4b53b2016201920222025202620282031Revenue JP¥53.0bEarnings JP¥7.4bAdvancedSet Fair ValueView all narrativesShin Nippon Biomedical Laboratories, Ltd. 競合他社Mesa LaboratoriesSymbol: NasdaqGS:MLABMarket cap: US$565.9mSotera HealthSymbol: NasdaqGS:SHCMarket cap: US$5.0bStevanato GroupSymbol: NYSE:STVNMarket cap: US$4.9bQiagenSymbol: NYSE:QGENMarket cap: US$8.2b価格と性能株価の高値、安値、推移の概要Shin Nippon Biomedical Laboratories過去の株価現在の株価JP¥7.0052週高値JP¥12.5752週安値JP¥7.00ベータ-0.251ヶ月の変化-23.59%3ヶ月変化-23.59%1年変化n/a3年間の変化n/a5年間の変化n/aIPOからの変化-58.75%最新ニュースお知らせ • Jun 17Shin Nippon Biomedical Laboratories, Ltd. to Report Q1, 2027 Results on Aug 05, 2026Shin Nippon Biomedical Laboratories, Ltd. announced that they will report Q1, 2027 results on Aug 05, 2026お知らせ • May 11Shin Nippon Biomedical Laboratories, Ltd., Annual General Meeting, Jun 26, 2026Shin Nippon Biomedical Laboratories, Ltd., Annual General Meeting, Jun 26, 2026.お知らせ • May 09Shin Nippon Biomedical Laboratories, Ltd. to Report Fiscal Year 2026 Results on May 11, 2026Shin Nippon Biomedical Laboratories, Ltd. announced that they will report fiscal year 2026 results on May 11, 2026お知らせ • May 02Shin Nippon Biomedical Laboratories, Ltd., Annual General Meeting, Apr 30, 2026Shin Nippon Biomedical Laboratories, Ltd., Annual General Meeting, Apr 30, 2026. Agenda: To change the Company's representatives and to assign executive members as described below; and to consider AGM.お知らせ • Dec 10Shin Nippon Biomedical Laboratories, Ltd. to Report Q3, 2026 Results on Feb 06, 2026Shin Nippon Biomedical Laboratories, Ltd. announced that they will report Q3, 2026 results on Feb 06, 2026お知らせ • Aug 16Shin Nippon Biomedical Laboratories, Ltd. to Report Q2, 2026 Results on Nov 07, 2025Shin Nippon Biomedical Laboratories, Ltd. announced that they will report Q2, 2026 results on Nov 07, 2025最新情報をもっと見るRecent updatesお知らせ • Jun 17Shin Nippon Biomedical Laboratories, Ltd. to Report Q1, 2027 Results on Aug 05, 2026Shin Nippon Biomedical Laboratories, Ltd. announced that they will report Q1, 2027 results on Aug 05, 2026お知らせ • May 11Shin Nippon Biomedical Laboratories, Ltd., Annual General Meeting, Jun 26, 2026Shin Nippon Biomedical Laboratories, Ltd., Annual General Meeting, Jun 26, 2026.お知らせ • May 09Shin Nippon Biomedical Laboratories, Ltd. to Report Fiscal Year 2026 Results on May 11, 2026Shin Nippon Biomedical Laboratories, Ltd. announced that they will report fiscal year 2026 results on May 11, 2026お知らせ • May 02Shin Nippon Biomedical Laboratories, Ltd., Annual General Meeting, Apr 30, 2026Shin Nippon Biomedical Laboratories, Ltd., Annual General Meeting, Apr 30, 2026. Agenda: To change the Company's representatives and to assign executive members as described below; and to consider AGM.お知らせ • Dec 10Shin Nippon Biomedical Laboratories, Ltd. to Report Q3, 2026 Results on Feb 06, 2026Shin Nippon Biomedical Laboratories, Ltd. announced that they will report Q3, 2026 results on Feb 06, 2026お知らせ • Aug 16Shin Nippon Biomedical Laboratories, Ltd. to Report Q2, 2026 Results on Nov 07, 2025Shin Nippon Biomedical Laboratories, Ltd. announced that they will report Q2, 2026 results on Nov 07, 2025お知らせ • Jun 13Shin Nippon Biomedical Laboratories, Ltd. to Report Q1, 2026 Results on Aug 05, 2025Shin Nippon Biomedical Laboratories, Ltd. announced that they will report Q1, 2026 results on Aug 05, 2025お知らせ • May 08Shin Nippon Biomedical Laboratories, Ltd., Annual General Meeting, Jun 27, 2025Shin Nippon Biomedical Laboratories, Ltd., Annual General Meeting, Jun 27, 2025.お知らせ • May 01Satsuma Pharmaceuticals Announces U.S. FDA Approval for Atzumi™ (Dihydroergotamine) Nasal Powder for the Acute Treatment of MigraineSatsuma Pharmaceuticals Inc. and its corporate parent, Shin Nippon Biomedical Laboratories, Ltd. announced that the U.S. Food and Drug Administration (FDA) has approved a 505(b)(2) New Drug Application (NDA) for Atzumi™ (dihydroergotamine (DHE)) nasal powder for the acute treatment of migraine with or without aura in adults. Atzumi was previously known as STS101. It is the second leading cause of disability worldwide in terms of time lost to disability and most common cause of disability among young women. The product is designed to provide patients an easy-to-use and easy-to-carry treatment option. The FDA approval for Atzumi is based on two clinical studies (Phase 1 PK trial and ASCEND Phase 3 open-label, long-term safety trial), which demonstrated fast absorption, rapid achievement of high DHE plasma concentrations, and sustained DHE plasma levels over time as well as safety and tolerability in subjects with migraine.お知らせ • Mar 05Shin Nippon Biomedical Laboratories, Ltd. to Report Fiscal Year 2025 Results on May 08, 2025Shin Nippon Biomedical Laboratories, Ltd. announced that they will report fiscal year 2025 results on May 08, 2025お知らせ • Dec 19Shin Nippon Biomedical Laboratories, Ltd. to Report Q3, 2025 Results on Feb 05, 2025Shin Nippon Biomedical Laboratories, Ltd. announced that they will report Q3, 2025 results on Feb 05, 2025お知らせ • Nov 26Satsuma Pharmaceuticals, Inc. and Shin Nippon Biomedical Laboratories, Ltd. Receive FDA Acceptance of NDA Resubmission of STS101 for the Acute Treatment of Migraine with or Without AuraSatsuma Pharmaceuticals, Inc. and its corporate parent, Shin Nippon Biomedical Laboratories, Ltd. announced that the U.S. Food and Drug Administration (FDA) has accepted for review a resubmission to original new drug application (NDA) for the investigational product STS101 (dihydroergotamine nasal powder) for the acute treatment of migraine with or without aura as a complete response to their January 2024 action letter. The Prescription Drug User Fee Act (PDUFA) date is set as April 30, 2025. Almost 40 million people in the United States suffer from migraine, especially among working women in their 20s to 40s. The U.S. market for acute migraine medications is estimated to be over USD 1.0 Billion.お知らせ • Sep 19Shin Nippon Biomedical Laboratories, Ltd. to Report Q2, 2025 Results on Nov 06, 2024Shin Nippon Biomedical Laboratories, Ltd. announced that they will report Q2, 2025 results on Nov 06, 2024お知らせ • Jul 12Shin Nippon Biomedical Laboratories, Ltd. to Report Q1, 2025 Results on Aug 06, 2024Shin Nippon Biomedical Laboratories, Ltd. announced that they will report Q1, 2025 results on Aug 06, 2024お知らせ • May 10Shin Nippon Biomedical Laboratories, Ltd., Annual General Meeting, Jun 24, 2024Shin Nippon Biomedical Laboratories, Ltd., Annual General Meeting, Jun 24, 2024.お知らせ • Mar 02Shin Nippon Biomedical Laboratories, Ltd. to Report Fiscal Year 2024 Results on May 08, 2024Shin Nippon Biomedical Laboratories, Ltd. announced that they will report fiscal year 2024 results on May 08, 2024お知らせ • Feb 02Shin Nippon Biomedical Laboratories, Ltd. Provides Consolidated Earnings Guidance for the Year Ending March 31, 2024Shin Nippon Biomedical Laboratories, Ltd. provided consolidated earnings guidance for the year ending March 31, 2024. For the period, the company expects revenue of ¥26,190 million, Operating profit of ¥3,470 million, Profit attributable to owners of parent of ¥3,975 million or ¥95.47 basic per share.お知らせ • Dec 06Shin Nippon Biomedical Laboratories, Ltd. to Report Q3, 2024 Results on Feb 02, 2024Shin Nippon Biomedical Laboratories, Ltd. announced that they will report Q3, 2024 results on Feb 02, 2024お知らせ • Nov 07Shin Nippon Biomedical Laboratories, Ltd. Announces Interim Dividend for the Year Ending 2024, Payable on November 30, 2023; Provides Dividend Guidance for the Year Ending 2024Shin Nippon Biomedical Laboratories, Ltd. announced that it was resolved at its Board of Directors' meeting November 7, 2023 that interim dividends of ¥20.00 shall be paid from retained earnings to shareholders on the record date of September 30, 2023. Effective date November 30, 2023.For the year ending 2024, the company expects to pay a dividend of JPY 30.00 per share.お知らせ • Aug 30Shin Nippon Biomedical Laboratories, Ltd. to Report Q2, 2024 Results on Nov 07, 2023Shin Nippon Biomedical Laboratories, Ltd. announced that they will report Q2, 2024 results on Nov 07, 2023お知らせ • Jun 17Satsuma Pharmaceuticals and Shin Nippon Biomedical Laboratories, Ltd. Announce Three Abstracts on STS101 for the Acute Treatment of Migraine to Be Presented at the American Headache Society's 65th Annual Scientific MeetingSatsuma Pharmaceuticals Inc. and its corporate parent, Shin Nippon Biomedical Laboratories Ltd. announced that three abstracts describing efficacy and safety results from the STS101 Phase 3 efficacy trial were selected for presentation at the American Headache Society's (AHS) 65th Annual Scientific Meeting. The 2023 meeting will be held in a hybrid virtual and in-person format at the JW Marriott in Austin, Texas from June 15 to June 18, 2023. Full abstracts are now available on the AHS website and will be published in the journal Headache®?.お知らせ • Jun 09Shin Nippon Biomedical Laboratories, Ltd. (TSE:2395) completed the acquisition of the remaining 91.6% stake in Satsuma Pharmaceuticals, Inc. (NasdaqGM:STSA) from a group of sellers.Shin Nippon Biomedical Laboratories, Ltd. (TSE:2395) entered into an agreement to acquire the remaining 91.6% stake in Satsuma Pharmaceuticals, Inc. (NasdaqGM:STSA) from a group of sellers for $27.6 million on April 16, 2023. Under the terms of the transaction SNBL will acquire all the remaining shares of common stock of Satsuma through a tender offer, for a price of $0.91 per share in cash. In addition, SNBL will issue one non-tradeable CVR, represents the right to additional payments of up to $5.77 per share, in total in the event where Satsuma’s STS101 is approved by the FDA and commercialized, and SNBL achieves cumulative financial return objectives of up to $500 million. The purchase price will be funded from existing cash. Post the completion of the transaction, SNBL will hold 100% stake in Satsuma. The merger agreement also provides that the payment of a $905,136 termination fee will be payable by Satsuma to Shin Nippon. As part of the merger, Satsuma will terminate the employment of each of John Kollins, President and Chief Executive Officer of the Company, and Tom O’Neil, Chief Financial Officer of the Company, effective as of the closing of the Offer. Prior to the closing, such executive officers shall remain in their current positions with their current compensation.The transaction is subject to the tender of a majority of Satsuma’s outstanding shares, minimum cash condition and other customary closing conditions. The transaction has been unanimously approved by the Board of Directors of both SNBL and Satsuma. The tender offer period is planned from April 2023 to May 2023, with the initial period of the tender offer to commence within 15 business days following the execution of definitive agreement. The expiration of the tender offer is on June 5, 2023. American Stock Transfer & Trust Company acted as transfer agent and depository bank to Satsuma. Joshua M. Dubofsky of Latham & Watkins LLP acted as legal advisor to Satsuma. Ian B. Edvalson of Wilson Sonsini Goodrich & Rosati P.C. acted as legal advisor to Wilson Sonsini Goodrich & Rosati P.C. Lazard acted as lead financial advisor and Houlihan Lokey Capital, Inc. acted as financial advisor and fairness opinion provider to Satsuma. D.F. King & Co., Inc. acted as information agent to Satsuma.Shin Nippon Biomedical Laboratories, Ltd. (TSE:2395) completed the acquisition of the remaining 91.6% stake in Satsuma Pharmaceuticals, Inc. (NasdaqGM:STSA) from a group of sellers on June 8, 2023. The Offer expired at the end of June 5, 2023. Total of 21,979,704 Shares were validly tendered and not validly withdrawn pursuant to the Offer, which represented approximately 66.0618% of the fully-diluted capitalization of Satsuma.株主還元SBLO.FUS Life SciencesUS 市場7D0%10.3%-2.5%1Yn/a17.6%19.0%株主還元を見る業界別リターン: SBLO.FがUS Life Sciences業界に対してどのようなパフォーマンスを示したかを判断するにはデータが不十分です。リターン対市場: SBLO.F US市場に対してどのようなパフォーマンスを示したかを判断するにはデータが不十分です。価格変動Is SBLO.F's price volatile compared to industry and market?SBLO.F volatilitySBLO.F Average Weekly Movementn/aLife Sciences Industry Average Movement8.7%Market Average Movement7.3%10% most volatile stocks in US Market16.8%10% least volatile stocks in US Market3.1%安定した株価: SBLO.Fの株価は、 US市場と比較して過去 3 か月間で変動しています。時間の経過による変動: 過去 1 年間のSBLO.Fのボラティリティの変化を判断するには データが不十分です。会社概要設立従業員CEO（最高経営責任者ウェブサイト19571,522Ryoichi Nagatawww.snbl.co.jp株式会社新日本バイオメディカル研究所は、受託研究機関として、国内外におけるトランザクショナルリサーチ事業およびメディポリス事業を展開しています。単回/反復投与毒性試験、抗原性試験、皮膚感作性試験、遺伝毒性試験、がん原性試験、局所刺激性試験、吸入毒性試験、TK試験、特性試験、安定性試験、依存性試験、生殖発生毒性試験、安全性薬理試験、薬物動態試験などの非臨床試験を提供している。また、治験責任医師パンフレット作成支援、治験実施計画書作成支援、治験医療機関、治験薬割付、治験依頼・契約、モニタリング、品質管理、データ管理、統計解析業務、総括報告書作成支援、電子申請支援、薬事コンサルティング、インフォームド・コンセント文書作成支援業務も行っている。また、治験施設管理機関サービス、臨床開発業務受託機関サービス、ワクチン・治療薬、抗体医薬、核酸医薬、ペプチド医薬、遺伝子治療、再生医療などの研究開発を含むトランスレーショナルリサーチサービスも提供している。さらに、地熱発電事業、ホテル宿泊施設運営事業、ウェルビーイング事業、清掃・事務・福祉サービス事業なども手掛けている。新日本バイオメディカル研究所は1957年に設立され、鹿児島に本社を置く。もっと見るShin Nippon Biomedical Laboratories, Ltd. 基礎のまとめShin Nippon Biomedical Laboratories の収益と売上を時価総額と比較するとどうか。SBLO.F 基礎統計学時価総額US$287.39m収益（TTM）US$28.22m売上高(TTM)US$201.00m10.4xPER（株価収益率1.5xP/SレシオSBLO.F は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計SBLO.F 損益計算書（TTM）収益JP¥32.52b売上原価JP¥18.29b売上総利益JP¥14.24bその他の費用JP¥9.67b収益JP¥4.57b直近の収益報告Mar 31, 2026次回決算日Aug 05, 2026一株当たり利益（EPS）109.69グロス・マージン43.78%純利益率14.04%有利子負債／自己資本比率93.8%SBLO.F の長期的なパフォーマンスは？過去の実績と比較を見る配当金4.4%現在の配当利回り46%配当性向View Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/06/29 21:11終値2026/06/09 00:00収益2026/03/31年間収益2026/03/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社の Github ページ でご覧いただけます。また、レポートの使い方に関する ガイド や YouTube の チュートリアル もご用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Shin Nippon Biomedical Laboratories, Ltd. 2 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。6 アナリスト機関Yuki TsukamotoBofA Global ResearchAkitada IwasaDaiwa Securities Co. Ltd.Stephen BarkerJefferies LLC3 その他のアナリストを表示
お知らせ • Jun 17Shin Nippon Biomedical Laboratories, Ltd. to Report Q1, 2027 Results on Aug 05, 2026Shin Nippon Biomedical Laboratories, Ltd. announced that they will report Q1, 2027 results on Aug 05, 2026
お知らせ • May 11Shin Nippon Biomedical Laboratories, Ltd., Annual General Meeting, Jun 26, 2026Shin Nippon Biomedical Laboratories, Ltd., Annual General Meeting, Jun 26, 2026.
お知らせ • May 09Shin Nippon Biomedical Laboratories, Ltd. to Report Fiscal Year 2026 Results on May 11, 2026Shin Nippon Biomedical Laboratories, Ltd. announced that they will report fiscal year 2026 results on May 11, 2026
お知らせ • May 02Shin Nippon Biomedical Laboratories, Ltd., Annual General Meeting, Apr 30, 2026Shin Nippon Biomedical Laboratories, Ltd., Annual General Meeting, Apr 30, 2026. Agenda: To change the Company's representatives and to assign executive members as described below; and to consider AGM.
お知らせ • Dec 10Shin Nippon Biomedical Laboratories, Ltd. to Report Q3, 2026 Results on Feb 06, 2026Shin Nippon Biomedical Laboratories, Ltd. announced that they will report Q3, 2026 results on Feb 06, 2026
お知らせ • Aug 16Shin Nippon Biomedical Laboratories, Ltd. to Report Q2, 2026 Results on Nov 07, 2025Shin Nippon Biomedical Laboratories, Ltd. announced that they will report Q2, 2026 results on Nov 07, 2025
お知らせ • Jun 17Shin Nippon Biomedical Laboratories, Ltd. to Report Q1, 2027 Results on Aug 05, 2026Shin Nippon Biomedical Laboratories, Ltd. announced that they will report Q1, 2027 results on Aug 05, 2026
お知らせ • May 11Shin Nippon Biomedical Laboratories, Ltd., Annual General Meeting, Jun 26, 2026Shin Nippon Biomedical Laboratories, Ltd., Annual General Meeting, Jun 26, 2026.
お知らせ • May 09Shin Nippon Biomedical Laboratories, Ltd. to Report Fiscal Year 2026 Results on May 11, 2026Shin Nippon Biomedical Laboratories, Ltd. announced that they will report fiscal year 2026 results on May 11, 2026
お知らせ • May 02Shin Nippon Biomedical Laboratories, Ltd., Annual General Meeting, Apr 30, 2026Shin Nippon Biomedical Laboratories, Ltd., Annual General Meeting, Apr 30, 2026. Agenda: To change the Company's representatives and to assign executive members as described below; and to consider AGM.
お知らせ • Dec 10Shin Nippon Biomedical Laboratories, Ltd. to Report Q3, 2026 Results on Feb 06, 2026Shin Nippon Biomedical Laboratories, Ltd. announced that they will report Q3, 2026 results on Feb 06, 2026
お知らせ • Aug 16Shin Nippon Biomedical Laboratories, Ltd. to Report Q2, 2026 Results on Nov 07, 2025Shin Nippon Biomedical Laboratories, Ltd. announced that they will report Q2, 2026 results on Nov 07, 2025
お知らせ • Jun 13Shin Nippon Biomedical Laboratories, Ltd. to Report Q1, 2026 Results on Aug 05, 2025Shin Nippon Biomedical Laboratories, Ltd. announced that they will report Q1, 2026 results on Aug 05, 2025
お知らせ • May 08Shin Nippon Biomedical Laboratories, Ltd., Annual General Meeting, Jun 27, 2025Shin Nippon Biomedical Laboratories, Ltd., Annual General Meeting, Jun 27, 2025.
お知らせ • May 01Satsuma Pharmaceuticals Announces U.S. FDA Approval for Atzumi™ (Dihydroergotamine) Nasal Powder for the Acute Treatment of MigraineSatsuma Pharmaceuticals Inc. and its corporate parent, Shin Nippon Biomedical Laboratories, Ltd. announced that the U.S. Food and Drug Administration (FDA) has approved a 505(b)(2) New Drug Application (NDA) for Atzumi™ (dihydroergotamine (DHE)) nasal powder for the acute treatment of migraine with or without aura in adults. Atzumi was previously known as STS101. It is the second leading cause of disability worldwide in terms of time lost to disability and most common cause of disability among young women. The product is designed to provide patients an easy-to-use and easy-to-carry treatment option. The FDA approval for Atzumi is based on two clinical studies (Phase 1 PK trial and ASCEND Phase 3 open-label, long-term safety trial), which demonstrated fast absorption, rapid achievement of high DHE plasma concentrations, and sustained DHE plasma levels over time as well as safety and tolerability in subjects with migraine.
お知らせ • Mar 05Shin Nippon Biomedical Laboratories, Ltd. to Report Fiscal Year 2025 Results on May 08, 2025Shin Nippon Biomedical Laboratories, Ltd. announced that they will report fiscal year 2025 results on May 08, 2025
お知らせ • Dec 19Shin Nippon Biomedical Laboratories, Ltd. to Report Q3, 2025 Results on Feb 05, 2025Shin Nippon Biomedical Laboratories, Ltd. announced that they will report Q3, 2025 results on Feb 05, 2025
お知らせ • Nov 26Satsuma Pharmaceuticals, Inc. and Shin Nippon Biomedical Laboratories, Ltd. Receive FDA Acceptance of NDA Resubmission of STS101 for the Acute Treatment of Migraine with or Without AuraSatsuma Pharmaceuticals, Inc. and its corporate parent, Shin Nippon Biomedical Laboratories, Ltd. announced that the U.S. Food and Drug Administration (FDA) has accepted for review a resubmission to original new drug application (NDA) for the investigational product STS101 (dihydroergotamine nasal powder) for the acute treatment of migraine with or without aura as a complete response to their January 2024 action letter. The Prescription Drug User Fee Act (PDUFA) date is set as April 30, 2025. Almost 40 million people in the United States suffer from migraine, especially among working women in their 20s to 40s. The U.S. market for acute migraine medications is estimated to be over USD 1.0 Billion.
お知らせ • Sep 19Shin Nippon Biomedical Laboratories, Ltd. to Report Q2, 2025 Results on Nov 06, 2024Shin Nippon Biomedical Laboratories, Ltd. announced that they will report Q2, 2025 results on Nov 06, 2024
お知らせ • Jul 12Shin Nippon Biomedical Laboratories, Ltd. to Report Q1, 2025 Results on Aug 06, 2024Shin Nippon Biomedical Laboratories, Ltd. announced that they will report Q1, 2025 results on Aug 06, 2024
お知らせ • May 10Shin Nippon Biomedical Laboratories, Ltd., Annual General Meeting, Jun 24, 2024Shin Nippon Biomedical Laboratories, Ltd., Annual General Meeting, Jun 24, 2024.
お知らせ • Mar 02Shin Nippon Biomedical Laboratories, Ltd. to Report Fiscal Year 2024 Results on May 08, 2024Shin Nippon Biomedical Laboratories, Ltd. announced that they will report fiscal year 2024 results on May 08, 2024
お知らせ • Feb 02Shin Nippon Biomedical Laboratories, Ltd. Provides Consolidated Earnings Guidance for the Year Ending March 31, 2024Shin Nippon Biomedical Laboratories, Ltd. provided consolidated earnings guidance for the year ending March 31, 2024. For the period, the company expects revenue of ¥26,190 million, Operating profit of ¥3,470 million, Profit attributable to owners of parent of ¥3,975 million or ¥95.47 basic per share.
お知らせ • Dec 06Shin Nippon Biomedical Laboratories, Ltd. to Report Q3, 2024 Results on Feb 02, 2024Shin Nippon Biomedical Laboratories, Ltd. announced that they will report Q3, 2024 results on Feb 02, 2024
お知らせ • Nov 07Shin Nippon Biomedical Laboratories, Ltd. Announces Interim Dividend for the Year Ending 2024, Payable on November 30, 2023; Provides Dividend Guidance for the Year Ending 2024Shin Nippon Biomedical Laboratories, Ltd. announced that it was resolved at its Board of Directors' meeting November 7, 2023 that interim dividends of ¥20.00 shall be paid from retained earnings to shareholders on the record date of September 30, 2023. Effective date November 30, 2023.For the year ending 2024, the company expects to pay a dividend of JPY 30.00 per share.
お知らせ • Aug 30Shin Nippon Biomedical Laboratories, Ltd. to Report Q2, 2024 Results on Nov 07, 2023Shin Nippon Biomedical Laboratories, Ltd. announced that they will report Q2, 2024 results on Nov 07, 2023
お知らせ • Jun 17Satsuma Pharmaceuticals and Shin Nippon Biomedical Laboratories, Ltd. Announce Three Abstracts on STS101 for the Acute Treatment of Migraine to Be Presented at the American Headache Society's 65th Annual Scientific MeetingSatsuma Pharmaceuticals Inc. and its corporate parent, Shin Nippon Biomedical Laboratories Ltd. announced that three abstracts describing efficacy and safety results from the STS101 Phase 3 efficacy trial were selected for presentation at the American Headache Society's (AHS) 65th Annual Scientific Meeting. The 2023 meeting will be held in a hybrid virtual and in-person format at the JW Marriott in Austin, Texas from June 15 to June 18, 2023. Full abstracts are now available on the AHS website and will be published in the journal Headache®?.
お知らせ • Jun 09Shin Nippon Biomedical Laboratories, Ltd. (TSE:2395) completed the acquisition of the remaining 91.6% stake in Satsuma Pharmaceuticals, Inc. (NasdaqGM:STSA) from a group of sellers.Shin Nippon Biomedical Laboratories, Ltd. (TSE:2395) entered into an agreement to acquire the remaining 91.6% stake in Satsuma Pharmaceuticals, Inc. (NasdaqGM:STSA) from a group of sellers for $27.6 million on April 16, 2023. Under the terms of the transaction SNBL will acquire all the remaining shares of common stock of Satsuma through a tender offer, for a price of $0.91 per share in cash. In addition, SNBL will issue one non-tradeable CVR, represents the right to additional payments of up to $5.77 per share, in total in the event where Satsuma’s STS101 is approved by the FDA and commercialized, and SNBL achieves cumulative financial return objectives of up to $500 million. The purchase price will be funded from existing cash. Post the completion of the transaction, SNBL will hold 100% stake in Satsuma. The merger agreement also provides that the payment of a $905,136 termination fee will be payable by Satsuma to Shin Nippon. As part of the merger, Satsuma will terminate the employment of each of John Kollins, President and Chief Executive Officer of the Company, and Tom O’Neil, Chief Financial Officer of the Company, effective as of the closing of the Offer. Prior to the closing, such executive officers shall remain in their current positions with their current compensation.The transaction is subject to the tender of a majority of Satsuma’s outstanding shares, minimum cash condition and other customary closing conditions. The transaction has been unanimously approved by the Board of Directors of both SNBL and Satsuma. The tender offer period is planned from April 2023 to May 2023, with the initial period of the tender offer to commence within 15 business days following the execution of definitive agreement. The expiration of the tender offer is on June 5, 2023. American Stock Transfer & Trust Company acted as transfer agent and depository bank to Satsuma. Joshua M. Dubofsky of Latham & Watkins LLP acted as legal advisor to Satsuma. Ian B. Edvalson of Wilson Sonsini Goodrich & Rosati P.C. acted as legal advisor to Wilson Sonsini Goodrich & Rosati P.C. Lazard acted as lead financial advisor and Houlihan Lokey Capital, Inc. acted as financial advisor and fairness opinion provider to Satsuma. D.F. King & Co., Inc. acted as information agent to Satsuma.Shin Nippon Biomedical Laboratories, Ltd. (TSE:2395) completed the acquisition of the remaining 91.6% stake in Satsuma Pharmaceuticals, Inc. (NasdaqGM:STSA) from a group of sellers on June 8, 2023. The Offer expired at the end of June 5, 2023. Total of 21,979,704 Shares were validly tendered and not validly withdrawn pursuant to the Offer, which represented approximately 66.0618% of the fully-diluted capitalization of Satsuma.
